Skip to main content
. 2020 May 31;12(6):1420. doi: 10.3390/cancers12061420

Figure 11.

Figure 11

Time to 50% mortality (meeting NIH humane endpoint criteria for euthanasia). Treatment with TOL consistently extended the time to 50% survival for mice with 4T1 breast cancer homografts by approximately 1 week when compared to controls. One-way ANOVA revealed a main effect. * = p < 0.01 by Tukey II post-hoc comparisons.